Abstract：
OBJECTIVE: To investigate oral and dental late effects in survivors of childhood brain tumors medulloblastoma (MB) and central nervous system supratentorial primitive neuroectodermal tumor (CNS-PNET).
METHODS: This cross-sectional study assessed oral and dental late effects in MB/CNS-PNET survivors treated before 20 years of age, and with a minimum of 2 years since treatment. Participants went through an oral and radiographic examination. We assessed oral status using the decayed-missing-filled index (DMFT), oral dryness, maximum mouth opening (MMO), fungal infection, and registration of dental developmental disturbances (DDD) in the form of hypodontia, microdontia, and enamel hypoplasia.
RESULTS: The 46 participants\' mean age at enrolment was 27 ± 12.8 years and at treatment 8.5 ± 5.2 years, and the mean time since treatment was 18.9 ± 12 years. Over a third (35%) of survivors had reduced mouth opening (mean 29.3 ± 5.6 mm (range 16-35)). A significantly lower MMO was found in individuals treated ≤ 5 years compared to survivors treated > 5 years (p = 0.021). One or more DDD were registered in 30.4% of the survivors, with a significantly higher prevalence in individuals treated ≤ 5 years (p < 0.001). Hypodontia was the most prevalent type of DDD. There was no difference in DMFT score in relation to age at treatment. Oral dryness was not frequently reported or observed in these survivors.
CONCLUSIONS: Survivors of childhood MB/CNS-PNET are at risk of oral and dental late effects including reduced mouth opening and DDD. The risk is highest in survivors treated before the age of 5.
METHODS: This cross-sectional study assessed oral and dental late effects in MB/CNS-PNET survivors treated before 20 years of age, and with a minimum of 2 years since treatment. Participants went through an oral and radiographic examination. We assessed oral status using the decayed-missing-filled index (DMFT), oral dryness, maximum mouth opening (MMO), fungal infection, and registration of dental developmental disturbances (DDD) in the form of hypodontia, microdontia, and enamel hypoplasia.
RESULTS: The 46 participants\' mean age at enrolment was 27 ± 12.8 years and at treatment 8.5 ± 5.2 years, and the mean time since treatment was 18.9 ± 12 years. Over a third (35%) of survivors had reduced mouth opening (mean 29.3 ± 5.6 mm (range 16-35)). A significantly lower MMO was found in individuals treated ≤ 5 years compared to survivors treated > 5 years (p = 0.021). One or more DDD were registered in 30.4% of the survivors, with a significantly higher prevalence in individuals treated ≤ 5 years (p < 0.001). Hypodontia was the most prevalent type of DDD. There was no difference in DMFT score in relation to age at treatment. Oral dryness was not frequently reported or observed in these survivors.
CONCLUSIONS: Survivors of childhood MB/CNS-PNET are at risk of oral and dental late effects including reduced mouth opening and DDD. The risk is highest in survivors treated before the age of 5.
摘要：
目的：探讨儿童脑肿瘤髓母细胞瘤（MB）和中枢神经系统幕上原始神经外胚层瘤（CNS-PNET）幸存者的口腔和牙齿晚期效应。
方法：这项横断面研究评估了在20岁之前接受治疗的MB/CNS-PNET幸存者的口腔和牙科晚期影响，治疗后至少2年。参与者进行了口腔和影像学检查。我们使用腐烂缺失填充指数(DMFT)评估口腔状态，口腔干燥，最大开口(MMO),真菌感染,以及以牙体发育不良形式记录牙齿发育障碍（DDD），microdontia,牙釉质发育不全.
结果：46名参与者的平均年龄为27±12.8岁，接受治疗的平均年龄为8.5±5.2岁，自治疗以来的平均时间为18.9±12年。超过三分之一（35％）的幸存者张口减少（平均29.3±5.6mm（范围16-35））。与治疗>5年的幸存者相比，治疗≤5年的个体的MMO显着降低（p=0.021）。在30.4％的幸存者中注册了一个或多个DDD，在治疗≤5年的个体中，患病率明显更高（p<0.001）。缺牙症是最普遍的DDD类型。DMFT评分与治疗时的年龄没有差异。在这些幸存者中不经常报告或观察到口腔干燥。
结论：儿童MB/CNS-PNET的幸存者面临口腔和牙科晚期影响的风险，包括张口减少和DDD。在5岁之前接受治疗的幸存者中风险最高。
方法：这项横断面研究评估了在20岁之前接受治疗的MB/CNS-PNET幸存者的口腔和牙科晚期影响，治疗后至少2年。参与者进行了口腔和影像学检查。我们使用腐烂缺失填充指数(DMFT)评估口腔状态，口腔干燥，最大开口(MMO),真菌感染,以及以牙体发育不良形式记录牙齿发育障碍（DDD），microdontia,牙釉质发育不全.
结果：46名参与者的平均年龄为27±12.8岁，接受治疗的平均年龄为8.5±5.2岁，自治疗以来的平均时间为18.9±12年。超过三分之一（35％）的幸存者张口减少（平均29.3±5.6mm（范围16-35））。与治疗>5年的幸存者相比，治疗≤5年的个体的MMO显着降低（p=0.021）。在30.4％的幸存者中注册了一个或多个DDD，在治疗≤5年的个体中，患病率明显更高（p<0.001）。缺牙症是最普遍的DDD类型。DMFT评分与治疗时的年龄没有差异。在这些幸存者中不经常报告或观察到口腔干燥。
结论：儿童MB/CNS-PNET的幸存者面临口腔和牙科晚期影响的风险，包括张口减少和DDD。在5岁之前接受治疗的幸存者中风险最高。
